EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study

Samuel Yamshon iD, Jean L Koff iD, Melissa C Larson iD, Brad S Kahl iD, Carla Casulo iD, Izidore S Lossos iD, Sara Haddadi, Michele Stanchina iD, Dai Chihara iD, Amy Ayers, Thomas M Habermann iD, Yucai Wang iD und 18 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27630 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Samuel Yamshon und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCohort StudiesDeoxycytidineDisease-Free SurvivalGemcitabineImmunotherapy, AdoptiveOxaliplatinRecurrenceRetrospective StudiesRituximabTreatment Outcome

Stichwörter der Autor:innen

chemotherapydiffuse large B‐cell lymphomalymphomareal‐world data

Substanzen

DeoxycytidineGemcitabineOxaliplatinRituximab

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Wilmot Cancer Institute, University of Rochester, Rochester, New York, USA.
  • Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.

ORCID-Profile: Samuel Yamshon, Jean L Koff, Melissa C Larson, Brad S Kahl, Carla Casulo, Izidore S Lossos, Michele Stanchina, Dai Chihara, Thomas M Habermann, Yucai Wang, Arushi Khurana, Grzegorz S Nowakowski, Umar Farooq, Brian K Link, Jonathon B Cohen, Jia Li, Ashwini Shewade, Connie Lee Batlevi, Andrea Lo-Rossi, David Fox, Anthony Masaquel, James R Cerhan, Matthew J Maurer

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Genentech
  • National Institutes of Health

Zitieren

APA

Yamshon, S., Koff, J. L., Larson, M. C., Kahl, B. S., Casulo, C., Lossos, I. S., Haddadi, S., Stanchina, M., Chihara, D., Ayers, A., Habermann, T. M., Wang, Y., Khurana, A., Nowakowski, G. S., Reicks, T. W., Farooq, U., Link, B. K., Cohen, J. B., Martin, P., …, & Nastoupil, L. J. (2025). Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study. American Journal of Hematology. https://doi.org/10.1002/ajh.27630

Vancouver

Yamshon S, Koff JL, Larson MC, Kahl BS, Casulo C, Lossos IS, et al. Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study. American Journal of Hematology. 2025. doi:10.1002/ajh.27630

BibTeX
@article{Yamshon2025,
  author = {Yamshon, Samuel and Koff, Jean L and Larson, Melissa C and Kahl, Brad S and Casulo, Carla and Lossos, Izidore S and Haddadi, Sara and Stanchina, Michele and Chihara, Dai and Ayers, Amy and Habermann, Thomas M and Wang, Yucai and Khurana, Arushi and Nowakowski, Grzegorz S and Reicks, Tanner W and Farooq, Umar and Link, Brian K and Cohen, Jonathon B and Martin, Peter and Li, Jia and Shewade, Ashwini and Batlevi, Connie Lee and Lo-Rossi, Andrea and Fox, David and Masaquel, Anthony and Mun, Yong and Cerhan, James R and Flowers, Christopher R and Maurer, Matthew J and Nastoupil, Loretta J},
  title = {Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27630}
}
Kostenlos starten →